Organization
Nanfang Hospital
10 abstracts
Abstract
Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.Org: Sun Yat-sen University Cancer Center, Clinical Research Design Division, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Nanfang Hospital, Sun Yat-sen Memorial Hospital,
Abstract
An MRI-based multi-parameter clinical decision support system (NeoMDSS) for early prediction of pathological complete response after the first cycle of neoadjuvant therapy in breast cancer: A multi-center prospective observational cohort study.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Academy of Medical Sciences, Southern Medical University, Department of Vascular Surgery,
Abstract
FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Nanfang Hospital, Southern Medical University,
Abstract
Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.Org: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Chinese Academy of Medical Science & Peking Union Medical Co,
Abstract
A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML).Org: Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanfang Hospital, Phase I Clinical Research Room,Nanfang Hospital Southern Medical University, Guangzhou, China,
Abstract
Genomic landscape of CDK6 amplification and its potential prognostic value in adult-type diffuse gliomas.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Nanfang Hospital, Southern Medical University, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Landscape of FGFR2/3 alterations in hepatobiliary malignancies.Org: Nanfang Hospital, Southern Medical University, Guangzhou, China, AcornMed Biotechnology Co., Ltd., Beijing, China, Beijing, China,
Abstract
A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
A 9-gene signature in circulating tumor DNA based on molecular residual disease detection to predict recurrence of resectable non–small-cell lung cancer.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Berry Oncology Corporation,